C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.260
-0.030 (-1.31%)
Jul 25, 2025, 4:00 PM - Market closed
C4 Therapeutics Employees
C4 Therapeutics had 110 employees as of December 31, 2024. The number of employees decreased by 35 or -24.14% compared to the previous year.
Employees
110
Change (1Y)
-35
Growth (1Y)
-24.14%
Revenue / Employee
$361,664
Profits / Employee
-$938,882
Market Cap
160.48M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 110 | -35 | -24.14% |
Dec 31, 2023 | 145 | -1 | -0.68% |
Dec 31, 2022 | 146 | 25 | 20.66% |
Dec 31, 2021 | 121 | 22 | 22.22% |
Dec 31, 2020 | 99 | 11 | 12.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CCCC News
- 5 weeks ago - C4 Therapeutics: An Entry Point If There's Ever Going To Be One - Seeking Alpha
- 2 months ago - C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - C4 Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 8 months ago - C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - GlobeNewsWire
- 8 months ago - C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewsWire
- 9 months ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 months ago - C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - GlobeNewsWire